Mingxing Wang, PhDMingxing Wang, PhD
Research Scientist, Drug/Gene Delivery Group
McColl-Lockwood Laboratory for Muscular Dystrophy Research
Department of Neurology 

Prior Positions and Experience

2005-2008: Postdoctoral Research Fellow, University of North Carolina, Charlotte, Department of Chemistry, University of North Carolina – Charlotte,  (Charlotte, USA)
2004-2005: Postdoctoral Research Fellow, supported by Japan Science and Technology Agency, Research Institute for Advanced Science and Technology, Osaka Prefecture University (Osaka, Japan) 
1997-2000: Lecturer,College of Chemistry and Chemical Engineering, Liaoning University (Shenyang, China)
1992- 1997: Engineer,Research Institute of Photographic Materials and Chemical Industry, the Ministry of Chemical Industry (Shenyang, China)


PhD:   2004, Gifu University (Gifu, Japan)
ME    1992, Shenyang Research Institution of Chemical Industry (Shenyang, China)
BS:     1989, Liaoning University (Shenyang, China)

Research Field

Dr. Wang’s research centrally involves application-directed molecular design, synthesis, and characterization of novel functional organic/polymeric materials for biomedicine, opto-electronic devices, and nanotechnology applications.  

Dr. Wang’s current research focus is “Design and evaluation of new polymers/peptides as gene/antisense oligonucleotide (AO) delivery vehicle for treating muscular dystrophies and other diseases”. Gene therapy and AO therapy both have potential for treating genetic diseases and disorders, especially, AO-mediated exon-skipping therapy has shown potential for treating Duchenne muscular dystrophy (DMD) in both animal models and in Phase I/II clinic trials. However, systemic exon-skipping and induction of dystrophin protein by current AO only have been limited to a proportion of dystrophic skeletal muscle fibers and are hardly detectable in the cardiac muscle due to low delivery efficiency. To develop effective and safe delivery vector is indispensable and the most challenge for successful gene/AO therapy.

Polymer-based non-viral vectors have been demonstrated more potential in drug/gene delivery, because they possess some unique advantages for practical use such as easy manipulation, low cytotoxicity, controlled release, stimuli-reactive, and even targeted delivery. The goals of Dr. Wang’s research are to develop a safe and effective polymer-based vehicles and corresponding delivery system for gene/AO therapy. We use a strategy of hypothesis-driven and discovery-oriented technique to design biocompatible, biodegradable polymers and corresponding polymer/peptide-AO conjugates, as well as optimal delivery formulation that will accelerate the transition of any experimental therapy to clinics.

Selected Peer-Reviewed Publications

Wang M, Wu B, Lu PJ, Tucker JD, Milazi S, Shah SN and Lu QL. Pluronic-PEI Copolymers Enhance Exon-skipping of 2’-OMethyl Phosphorothioate Oligonucleotide in Cell Culture and Dystrophic mdx Mice. Gene Therapy, 2013, accepted.

Wang M,Wu B, Lu PJ, Cloer C, Tucker JD, Lu QL. Polyethylenimine modified pluronics (PCMs) improve morpholino oligomer delivery” in cell culture and dystrophic mdx mice. Molecular Therapy, 2012, Nov 20. [PMID: 23164938].

Wang M, Tucker JD, Lu PJ, Wu B, Lu QL. Tris[2-(acryloyloxy)ethyl]isocyanurate cross-linked low-molecular-weight polyethylenimine as gene delivery carriers in cell culture and dystrophic mdx mice. Bioconjugate Chemistry. 2012. 23, 837−845. [PMID: 22443086]

Wang M, Lu PJ, Wu B, Tucker JD, Cloer C, Lu QL. High efficiency and low toxicity of polyethyleneimine modified Pluronics (PEI–Pluronic) as gene delivery carriers in cell culture and dystrophic mdx Mice, J. Mater. Chem. 2012, 22, 6038-6046. DOI: 10.1039/C2JM15625C

Gonsalves KE, Wang M, Lee CT, Yueh W, Tapia-tapia M, Batina N, Henderson CL. New chemically amplified resists incorporating anionic photoacid generator functional groups for sub-50 nm half-pitch lithography. J. Mater. Chem. 2009, 19(18), 2797-2802.  DOI: 10.1039/B818612J

Wang M, Lee CT,  Henderson CL, Yueh W,  Roberts JM, Gonsalves KE.  Incorporation of ionic photoacid generator and base quencher into polymer main chain for sub-50 nm resolution patterning”, J. Mater. Chem. 2008, 18, 2704-2708. DOI: 10.1039/B801517A

Wang M, Yueh W, Gonsalves KE. Novel anionic photoacid generators (PAGs) bound polymers resists for EUV lithography. Macromolecules, 2007, 40, 8220-8224.
Wang M, Gonsalves KE, Robinovich M, Yueh W, Roberts JM. Novel anionic photoacid generators (PAGs) and corresponding PAG bound polymers for sub-50 nm EUV lithography. J. Mater. Chem., 2007, 17(17), 1699-1706.  DOI: 10.1039/B617133H

Wang M, Xiao X, Fujiwaha H, Sugimoto T, Noguchi S, Ishida T, Mori T,  Katori HA. Antiferromagnetic or canted ferromagnetic orderings of Fe (III) d spins of FeX4- ions in BEDT-TTFVO(S) •FeX4 (X = Cl, Br) [BEDT-TTFVO(S) = bis (ethylenedithio)tetrathiafulvalenoquinone (-thioquione)-1, 3-dithiolemethide). Inorg. Chem. 2007, 46, 3049-3056.

Matsui M, Wang M, Funabiki K, Hayakawa Y, Kitaguchi T. Properties of novel perylene-3,4:9,10-tetracarboxidiimide-centred dendrimers and their application as emitters in organic electroluminescence devices. Dyes and Pigments, 2007, 74, 169-175. See article

Wang M, Jarnagin ND, Lee CT, Henderson CL, Yueh W, Roberts JM, Gonsalves KE.  Novel polymeric anionic photoacid generators (PAGs) and corresponding polymers for 193 nm lithography. J. Mater. Chem., 2006, 16, 3701-3707. DOI: 10.1039/B607918K

WangM , Gonsalves KE, Yueh W, Roberts JM. Novel anionic photoacid generators (PAGs) and corresponding PAG bound polymers. Macromolecular Rapid Communications, 2006, 27, 1590-1595. DOI: 10.1002/marc.200600330

Current, Recent and Pending Grant Support

Grant Title:Amphiphilic Polymer Modified PMO for Treating Duchenne Muscular Dystrophy by Exon-Skipping, “Grant #2011-BRG-1204”
Funding Agency: North Carolina Biotechnology Center
Role: Principal Investigator
Years: 07/2011-12/2012